Text
This innovation delivers vaccines through a painless, 10-second patch application that has demonstrated up to four times greater efficacy in clinical trials compared to traditional needle methods. The technology significantly reduces vaccine material requirements while enhancing production efficiency and profitability.
Founded in 2011, this biotech leader is addressing critical challenges in pandemic preparedness and global vaccine accessibility. Having secured over $310 million in funding and pursuing an additional $100 million in private investment, Vaxxas has validated its technology through human clinical trials and optimized it for large-scale manufacturing. The company represents one of the University of Queensland and UniQuest’s most significant commercialization success stories.
Founded in 2011, this biotech leader is addressing critical challenges in pandemic preparedness and global vaccine accessibility. Having secured over $310 million in funding and pursuing an additional $100 million in private investment, Vaxxas has validated its technology through human clinical trials and optimized it for large-scale manufacturing. The company represents one of the University of Queensland and UniQuest’s most significant commercialization success stories.
